Madrigal Pharmaceuticals
MDGL
124 hedge funds and large institutions have $1.38B invested in Madrigal Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 41 increasing their positions, 45 reducing their positions, and 12 closing their positions.
55% more call options, than puts
Call options by funds: $29.7M | Put options by funds: $19.2M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
8% more capital invested
Capital invested by funds: $1.27B → $1.38B (+$107M)
2.41% more ownership
Funds ownership: 72.96% → 75.37% (+2.4%)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
1% less funds holding
Funds holding: 125 → 124 (-1)
9% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 45
Top Buyers
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$58.6M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$20.4M |
| 3 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$18.8M |
| 4 |
N
Natixis
Paris,
France
|
+$8.59M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$8.04M |
Top Sellers
| 1 |
Jennison Associates
New York
|
-$20.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$18.9M |
| 3 |
HM
HealthCor Management
New York
|
-$7.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.58M |
| 5 |
Renaissance Technologies
New York
|
-$5.49M |
MDGL Hedge Fund Activity: Q3 2020 in Review
124 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2020, worth a combined $1.38B — up 8.4% from $1.27B a quarter earlier.
Fund positioning in MDGL was balanced in Q3 2020: 12 funds opened new positions, 12 closed out, 41 added to existing stakes and 45 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $58.6M. The largest seller was Jennison Associates, exiting entirely with an estimated $20.1M sold.
- 124 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2020, down from 125 in Q2 2020.
- Funds reported $1.38B of Madrigal Pharmaceuticals stock for Q3 2020, up 8.4% quarter-over-quarter.
- 12 funds opened new Madrigal Pharmaceuticals positions in Q3 2020 and 12 closed out, a net change of 0 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2020 was Avoro Capital Advisors, an estimated $58.6M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2020 was Jennison Associates, an estimated $20.1M sold.
Based on aggregated 13F filings for Q3 2020.